Trial reportProstate cancer and prostatic diseases2025
Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study.
Trial report in Prostate cancer and prostatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04523207 (A Multi-center, Open-label, Single-arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-center, Open-label, Single-arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy (ADT) in Treatment-naïve Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Who cites it
5 citing papers in PubMed.
- Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP).The Journal of urology · 2024Trial
- Severe Toxicodermia due to Apalutamide: A Case Report of DRESS in an Elderly Adult.International journal of hematology-oncology and stem cell research · 2026Article
- Apalutamide-induced severe cutaneous adverse reactions in prostate cancer: a comprehensive review of reported cases and clinical strategies.Frontiers in pharmacology · 2026Review
- Diagnosis and Management of Skin Toxicities in Systemic Treatment of Genitourinary Cancers.Cancers · 2025Review
- Apalutamide-associated rash combined with severe neutropenia and eosinophilia: a case report.AME case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesBased on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes. SUBJECTS/
methodsA prespecified rash management guide outlining recommended skin care practices was provided to all patients enrolled in Apa-RP (NCT04523207). Rash-related safety data from Apa-RP were compared descriptively with data from SPARTAN and TITAN.
resultsPatients in Apa-RP experienced improved rash-related outcomes vs those in SPARTAN and TITAN.
conclusionsIncreased vigilance and proactive management may reduce the incidence, severity, and duration of rash during apalutamide treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.